Chun-Wei Chen

Dr. Chun-Wei Chen

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SLStanley Lee
Stanley Lee
HDHeidi Dvinge
Heidi Dvinge
EKEunhee Kim
Eunhee Kim
HCHana Cho
Hana Cho
JMJean-Baptiste Micol
Jean-Baptiste Micol
OAOmar Abdel-Wahab
Omar Abdel-Wahab
Leukemias bearing heterozygous mutations in the SRSF2 splicing-factor-encoding gene can be therapeutically targeted by pharmacologic inhibition of residual spliceosome function. Mutations in genes encoding splicing factors (which we refer to as spliceosomal genes) are commonly found in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)1,2,3. These mutations recurrently affect specific amino acid residues, leading to perturbed normal splice site and exon recognition4,5,6. Spliceosomal gene mutations are always heterozygous and rarely occur together with one another, suggesting that cells may tolerate only a partial deviation from normal splicing activity. To test this hypothesis, we engineered mice to express a mutated allele of serine/arginine-rich splicing factor 2 (Srsf2P95H)—which commonly occurs in individuals with MDS and AML—in an inducible, hemizygous manner in hematopoietic cells. These mice rapidly succumbed to fatal bone marrow failure, demonstrating that Srsf2-mutated cells depend on the wild-type Srsf2 allele for survival. In the context of leukemia, treatment with the spliceosome inhibitor E7107 (refs. 7,8) resulted in substantial reductions in leukemic burden, specifically in isogenic mouse leukemias and patient-derived xenograft AMLs carrying spliceosomal mutations. Whereas E7107 treatment of mice resulted in widespread intron retention and cassette exon skipping in leukemic cells regardless of Srsf2 genotype, the magnitude of splicing inhibition following E7107 treatment was greater in Srsf2-mutated than in Srsf2-wild-type leukemia, consistent with the differential effect of E7107 on survival. Collectively, these data provide genetic and pharmacologic evidence that leukemias with spliceosomal gene mutations are preferentially susceptible to additional splicing perturbations in vivo as compared to leukemias without such mutations. Modulation of spliceosome function may thus provide a new therapeutic avenue in genetically defined subsets of individuals with MDS or AML.

12 May 2020 in Cell Stem Cell
Verified
Journal Article
Closed access
CSChao Shen
Chao Shen
YSYue Sheng
Yue Sheng
AZAllen C. Zhu
Allen C. Zhu
SRSean Robinson
Sean Robinson
XJXi Jiang
Xi Jiang
JCJianjun Chen
Jianjun Chen

10 February 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
RSRui Su
Rui Su
LDLei Dong
Lei Dong
YLYangchan Li
Yangchan Li
MGMin Gao
Min Gao
PHP. Cody He
P. Cody He
JCJianjun Chen
Jianjun Chen

1 March 2021 in Molecular Cell
Verified
Journal Article
Closed access
YQYing Qing
Ying Qing
LDLei Dong
Lei Dong
LGLei Gao
Lei Gao
CLChenying Li
Chenying Li
YLYangchan Li
Yangchan Li
JCJianjun Chen
Jianjun Chen

1 October 2016 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MKMichael W.M. Kühn
Michael W.M. Kühn
ESEvelyn Song
Evelyn Song
ZFZhaohui Feng
Zhaohui Feng
ASAmit Sinha
Amit Sinha
CCChun-Wei Chen
Chun-Wei Chen
SAScott A. Armstrong
Scott A. Armstrong
Homeobox (HOX) proteins and the receptor tyrosine kinase FLT3 are frequently highly expressed and mutated in acute myeloid leukemia (AML). Aberrant HOX expression is found in nearly all AMLs that harbor a mutation in the Nucleophosmin (NPM1) gene, and FLT3 is concomitantly mutated in approximately 60% of these cases. Little is known about how mutant NPM1 (NPM1mut) cells maintain aberrant gene expression. Here, we demonstrate that the histone modifiers MLL1 and DOT1L control HOX and FLT3 expression and differentiation in NPM1mut AML. Using a CRISPR/Cas9 genome editing domain screen, we show NPM1mut AML to be exceptionally dependent on the menin binding site in MLL1. Pharmacologic small-molecule inhibition of the menin–MLL1 protein interaction had profound antileukemic activity in human and murine models of NPM1mut AML. Combined pharmacologic inhibition of menin–MLL1 and DOT1L resulted in dramatic suppression of HOX and FLT3 expression, induction of differentiation, and superior activity against NPM1mut leukemia. Significance: MLL1 and DOT1L are chromatin regulators that control HOX, MEIS1, and FLT3 expression and are therapeutic targets in NPM1mut AML. Combinatorial small-molecule inhibition has synergistic on-target activity and constitutes a novel therapeutic concept for this common AML subtype. Cancer Discov; 6(10); 1166–81. ©2016 AACR. See related commentary by Hourigan and Aplan, p. 1087. This article is highlighted in the In This Issue feature, p. 1069

1 July 2017 in Molecular Cell
Verified
Journal Article
Closed access
SWShu-Ping Wang
Shu-Ping Wang
ZTZhanyun Tang
Zhanyun Tang
CCChun-Wei Chen
Chun-Wei Chen
MSMiho Shimada
Miho Shimada
RKRichard P. Koche
Richard P. Koche
RRRobert G. Roeder
Robert G. Roeder